Molecular Mechanisms of Reelin in the Enteric Nervous System and the Microbiota–Gut–Brain Axis: Implications for Depression and Antidepressant Therapy
-
Published:2024-01-09
Issue:2
Volume:25
Page:814
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Halvorson Ciara S.1, Sánchez-Lafuente Carla Liria1ORCID, Johnston Jenessa N.2, Kalynchuk Lisa E.1ORCID, Caruncho Hector J.1
Affiliation:
1. Division of Medical Sciences, University of Victoria, 3800 Finnerty Rd., Victoria, BC V8P 5C2, Canada 2. Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Abstract
Current pharmacological treatments for depression fail to produce adequate remission in a significant proportion of patients. Increasingly, other systems, such as the microbiome–gut–brain axis, are being looked at as putative novel avenues for depression treatment. Dysbiosis and dysregulation along this axis are highly comorbid with the severity of depression symptoms. The endogenous extracellular matrix protein reelin is present in all intestinal layers as well as in myenteric and submucosal ganglia, and its receptors are also present in the gut. Reelin secretion from subepithelial myofibroblasts regulates cellular migration along the crypt–villus axis in the small intestine and colon. Reelin brain expression is downregulated in mood and psychotic disorders, and reelin injections have fast antidepressant-like effects in animal models of depression. This review seeks to discuss the roles of reelin in the gastrointestinal system and propose a putative role for reelin actions in the microbiota–gut–brain axis in the pathogenesis and treatment of depression, primarily reflecting on alterations in gut epithelial cell renewal and in the clustering of serotonin transporters.
Funder
NSERC-DG CRC CIHR-PG
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference193 articles.
1. Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., and Iwata, N. (2011). Cross-National Epidemiology of DSM-IV Major Depressive Episode. BMC Med., 9. 2. Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder;Ruble;Psychiatr. Serv.,2017 3. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report;Rush;Am. J. Psychiatry,2006 4. Kim, J.-W., Suzuki, K., Kavalali, E.T., and Monteggia, L.M. (2023). Ketamine: Mechanisms and Relevance to Treatment of Depression. Annu. Rev. Med. 5. Söderquist, F., Syk, M., Just, D., Kurbalija Novicic, Z., Rasmusson, A.J., Hellström, P.M., Ramklint, M., and Cunningham, J.L. (2020). A Cross-Sectional Study of Gastrointestinal Symptoms, Depressive Symptoms and Trait Anxiety in Young Adults. BMC Psychiatry, 20.
|
|